Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591392 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL18610000 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL29819954 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL17239764 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL18474094 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4PIM1CHRNB4CHRNA3 | |
| SCHEMBL31436224 | 0.85 | PIM2 (0.35) | PPM1D | |
| SCHEMBL4156977 | 0.84 | CYP2D6 (0.42) | PPM1D | |
| SCHEMBL5343341 | 0.84 | CYP2D6 (0.42) | PPM1D | |
| SCHEMBL15145321 | 0.84 | CYP2D6 (0.42) | PPM1D | |
| SCHEMBL14865098 | 0.84 | CYP2D6 (0.42) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-18 | — | — | US | disclosed |
| US-10017497-B2 | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| WO-2015171722-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150313911-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | VERNALIS (R&D) LTD (GB) | 2015-11-05 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | XUE CHU-BIAO | 2009-11-19 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-0839828-A1 | Building blocks for DNA/PNA-Cooligomer | BAYER AG (DE) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | CHRNB2 637/4885CHRNA4 280/4885PIM1 4197/4885 |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | CHRNB2 4875/4885CHRNA4 4876/4885PIM1 2960/4885 |
| US-20150313911-A1 | INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, API5 | CHRNB2 2931/4885CHRNA4 1964/4885PIM1 2858/4885 |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | CHRNB2 637/4885CHRNA4 280/4885PIM1 4197/4885 |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | CHRNB2 637/4885CHRNA4 280/4885PIM1 4197/4885 |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | CHRNB2 1181/4885CHRNA4 1969/4885PIM1 1645/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | CHRNB2 637/4885CHRNA4 280/4885PIM1 4197/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CHRNB2 1239/4885CHRNA4 1979/4885PIM1 1528/4885 |
| US-10017497-B2 | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | GPR55, GPR65, GPR4 | CHRNB2 1519/4885CHRNA4 570/4885PIM1 3837/4885 |
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | CHRNB2 2482/4885CHRNA4 1365/4885PIM1 2789/4885 |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | CHRNB2 637/4885CHRNA4 280/4885PIM1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.